Quote
Carey
Interesting, but considering that their results differ dramatically from numerous previous studies
The important factor appears to better methods of staying within the INR range.
"In our study, the risk of intracranial bleeding was low in both groups, but numerically lower in the PSM group
and the low risk of intracranial bleeding in PSM patients is at least partly explained by the high quality of anticoagulant control with INR values within the target range in >70% of patients14."
Interesting that the warfarin group was a bit sicker:
"The PSM population included 20.4% with indication of heart failure, and patients with cancer (all types including any previous cancers) or chronic pulmonary disease accounted for 9.7% and 2.2%, respectively. By design, these patients were excluded in the DOAC cohort.."
"As detailed in Table 1, the CHA2DS2-Vasc score was slightly higher among patients treated with PSM"
Edited 1 time(s). Last edit at 11/01/2018 01:08AM by jpeters.